Related Experiment Videos

Proteinuria reduction: mandatory consideration or option when selecting an antihypertensive agent?

Robert D Toto1

  • 1University of Texas, Southwestern Medical Center Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390-8856, USA. robert.toto@utsouthwestern.edu

Current Hypertension Reports
|September 15, 2005
PubMed

Insights

Reducing proteinuria is crucial for managing cardiovascular disease and chronic kidney disease progression. Antihypertensive medications blocking the renin-angiotensin-aldosterone system (RAAS) are effective in lowering proteinuria and improving outcomes.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Proteinuria, including microalbuminuria, is a significant risk factor for cardiovascular disease and kidney disease progression.
  • Hypertension increases proteinuria risk, necessitating antihypertensive treatments that also reduce protein excretion.

Purpose of the Study:

  • To evaluate the role of proteinuria reduction in antihypertensive treatment selection.
  • To assess the efficacy of different antihypertensive agents in reducing proteinuria.

Main Methods:

  • Review of observational studies and intervention trials.
  • Analysis of clinical trial data on antihypertensive agents, including those blocking the renin-angiotensin-aldosterone system (RAAS).
  • Comparison of nondihydropyridine calcium channel blockers with ACE inhibitors and dihydropyridine calcium channel blockers in type 2 diabetics.

Main Results:

  • Lowering proteinuria in chronic kidney disease patients reduces progression to end-stage kidney disease and improves cardiovascular outcomes.
  • RAAS-blocking agents are generally more effective than other antihypertensives for proteinuria reduction.
  • Nondihydropyridine calcium channel blockers may be more effective than dihydropyridine calcium channel blockers in specific diabetic populations.

Conclusions:

  • Proteinuria reduction should be a mandatory consideration when selecting antihypertensive regimens.
  • Evidence supports the use of RAAS inhibitors and potentially nondihydropyridine calcium channel blockers for managing proteinuria.
  • Integrated management of hypertension, proteinuria, and cardiovascular/kidney disease is essential.

Related Concept Videos

Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...